Cartalax vs PEA
A side-by-side research comparison of Cartalax and PEA across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cartalax | PEA |
|---|---|---|
| Full name | Cartalax (Ala-Glu-Asp-Gly Cartilage Bioregulator) | Palmitoylethanolamide |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Research compound (peptide bioregulator) | Dietary supplement (medical food in EU) |
| Mechanism | As a signal peptide (Ala-Glu-Asp-Gly), it is proposed to regulate gene expression in chondrocytes and connective tissue, supporting cartilage matrix maintenance and anti-inflammatory tissue signaling. | Activates PPARĪ± nuclear receptors for anti-inflammatory gene transcription. Inhibits mast cell degranulation. Enhances endocannabinoid tone by inhibiting FAAH (increasing anandamide). Desensitizes TRPV1 pain channels via allosteric modulation. |
| Molecular weight | ~390 Da | 299.49 Da |
| Half-life | Short (peptide) | ~1-2 hours (micronized form extends effects) |
| Bioavailability | Oral (encapsulated) or subcutaneous | ~20% (standard); improved with micronized/ultra-micronized forms |
| Typical dose | ~1-2 capsules/day or short injectable courses | 300-1200 mg |
| Frequency | Once daily | 2-3x daily |
| Route | Oral capsule or subcutaneous | Oral (micronized preferred) |
Cartalax reported benefits
- Cartilage/joint tissue support
- Connective tissue maintenance (proposed)
- Anti-inflammatory tissue signaling
- Short course-based protocol
PEA reported benefits
- Chronic pain reduction
- Neuropathic pain relief
- Anti-inflammatory (mast cell stabilization)
- No tolerance or dependence
- Neuroprotection
- Safe with other medications
Related comparisons
Research and educational reference only. Not medical advice.